|Articles|June 1, 1998

June 1998
Volume 4
Issue 6

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Author(s)Michael T. Halpern, MD, PhD, Cynthia S. Palmer, MSc, C. Stephen Foster, MD

Download PDF: A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

about 28 years ago

Article

Correspondence regarding, "Screening and Surveillance for Colorectal Cancer"

about 28 years ago

Article

"Carving Out" Conditions From Global Capitation Rates: Protecting High-Cost Patients, Physicians, and Health Plans in a Managed Care Environment

about 28 years ago

Article

Delivery of Preventive Healthcare to Older African-American Patients: A Performance Comparison from Two Practice Models

about 28 years ago

Article

Insurance Type and the Transportation to Emergency Departments of Patients with Acute Cardiac Ischemia: The ACI-TIPI Trial Insurance Study

about 28 years ago

Article

Does Competition by Health Maintenance Organizations Affect the Adoption of Cost-Containment Measures by Fee-for-Service Plans?

about 28 years ago

Article

Safety and Clinical Efficacy of Zileuton in Patients with Chronic Asthma

about 28 years ago

Article

Identification and Case Management in an HMO of Patients at Risk of Preterm Labor

about 28 years ago

Article

A Closer Look at Lower Back Pain

about 28 years ago

Article

Food Borne Illnesses in the United States: Office Recognition and Management

about 28 years ago

Article

Rheumatoid Arthritis: Focus on Appropriate Drug Therapy

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

COVID-19 May Follow A Different Seasonal Pattern Than Influenza, RSV

What Comes Next: Taking on Unanswered Questions in Multiple Myeloma

New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000

Treatment for Thyroid Eye Disease Approved by FDA

FDA Expands Risankizumab Approval to Pediatric Plaque Psoriasis, Active PsA